Research shows that a protein called Twist1 directly causes dangerous changes in blood vessel cells that lead to plaque buildup and heart disease. According to Gram Research analysis, when scientists removed Twist1 from blood vessel cells in mice, plaques became smaller and more stable, less likely to rupture and cause heart attacks. This discovery identifies Twist1 as a key driver of inherited heart disease risk and suggests it could be a target for new treatments.
According to Gram Research analysis, scientists discovered that a protein called Twist1 plays a major role in making arteries more vulnerable to dangerous plaque buildup. Using advanced genetic studies in mice and human cells, researchers found that Twist1 causes the inner lining of blood vessels to change in ways that promote inflammation and plaque formation. When they removed Twist1 from blood vessel cells, plaques became smaller and more stable. This discovery helps explain why some people inherit higher risks for heart disease and could lead to new treatments targeting this specific protein.
Key Statistics
A 2026 research study in mice found that removing Twist1 from blood vessel cells reduced atherosclerotic plaque size and created more stable plaques less prone to rupture, compared to mice with normal Twist1 levels.
Research published in Arteriosclerosis, Thrombosis, and Vascular Biology identified Twist1 as a causal gene for multiple atherosclerotic vascular diseases, with the protein activating specifically in areas of abnormal blood flow where plaques form.
A 2026 analysis of human heart artery cells revealed that Twist1 simultaneously activates inflammatory and scar-forming gene programs in blood vessel cells, explaining why plaques become both more inflamed and unstable during atherosclerosis.
The Quick Take
- What they studied: How a protein called Twist1 changes the behavior of cells lining blood vessels and whether removing it could prevent dangerous plaque buildup in arteries
- Who participated: Genetically modified mice prone to heart disease, mice with Twist1 removed from blood vessel cells, and human heart artery cells grown in laboratory conditions
- Key finding: Removing Twist1 from blood vessel cells reduced plaque size and made plaques more stable and less likely to rupture and cause heart attacks
- What it means for you: This research identifies a specific target for future heart disease treatments, though these findings are still in early stages and haven’t been tested in humans yet
The Research Details
Researchers used multiple advanced techniques to understand how Twist1 affects blood vessel cells during atherosclerosis (plaque buildup in arteries). They studied genetically modified mice that naturally develop heart disease, feeding some a high-fat diet for 16 weeks to speed up plaque formation. They used cutting-edge single-cell genetic sequencing to examine individual cells and track which blood vessel cells changed during disease. They also created two different mouse models where Twist1 was specifically removed from blood vessel cells to see what happened. To confirm their findings applied to humans, they grew human heart artery cells in the lab, exposed them to different blood flow conditions, and added extra Twist1 to watch how it changed the cells’ behavior. Finally, they analyzed human genetic data from patients to validate that their mouse discoveries matched what happens in real people.
This research approach is important because previous studies suggested blood vessel cells change during heart disease, but scientists couldn’t clearly see where these changes happened or what caused them. By combining genetic tracking, detailed cell analysis, and human validation, this study provides clear evidence that Twist1 is a major driver of these dangerous changes. Understanding the exact mechanism helps scientists design targeted treatments rather than broad medications that affect many pathways.
This study is high-quality because it used multiple complementary techniques (genetic tracking, single-cell sequencing, and human cell validation) to confirm findings from different angles. The researchers tested their discoveries in two different mouse models to ensure results weren’t due to experimental artifacts. They validated key findings in human cells and human genetic data, which strengthens confidence that results apply beyond just mice. The study was published in a top-tier cardiovascular journal, indicating peer review by leading experts. However, the sample size of 12 refers to experimental groups rather than individual subjects, and findings still need testing in human clinical trials.
What the Results Show
The research revealed that during atherosclerosis, blood vessel cells undergo a dramatic transformation controlled by Twist1. These cells simultaneously activate two harmful programs: one that causes inflammation and another that makes them lose their normal identity and gain characteristics of scar-forming cells (a process called endothelial-to-mesenchymal transition). This dual activation makes plaques more dangerous and unstable. When researchers removed Twist1 specifically from blood vessel cells in mice, this transformation was significantly reduced. As a result, plaques became smaller and more stable, meaning they were less likely to rupture and cause heart attacks. The researchers identified specific molecules that Twist1 activates during this process, including CXCL12 and E-selectin, which are key drivers of inflammation and plaque instability. These findings were confirmed in human heart artery cells grown in the laboratory, suggesting the same mechanism operates in people.
The study revealed that a commonly used laboratory tool for studying Twist1 (called a conditional allele) wasn’t working as scientists thought, it reduced Twist1 in multiple cell types, not just blood vessel cells. This discovery is important because it means previous research conclusions may need re-evaluation. The researchers also found that blood flow conditions matter: Twist1 becomes active in areas of blood vessels exposed to abnormal, slow blood flow, exactly where plaques tend to form. This explains why plaques develop in specific locations rather than throughout the entire arterial system.
This research unifies several puzzling observations in the field. Previous studies using single-cell genetic analysis suggested blood vessel cells change during heart disease, but scientists couldn’t agree on exactly what was happening or where. Some studies suggested inflammation was key, others emphasized the mesenchymal transition. This work shows both processes happen together in the same cells, controlled by Twist1. The finding that Twist1 is a ‘causal gene’ (meaning it directly causes disease risk) explains why genetic studies have repeatedly identified this gene in people with inherited heart disease risk. By showing exactly how Twist1 causes problems, this research provides the missing link between genetic risk and actual disease development.
This study was conducted primarily in mice, which don’t perfectly replicate human heart disease. While researchers validated findings in human cells grown in dishes, these cells don’t experience the complex environment of a living human body. The study examined relatively short timeframes (16 weeks of high-fat diet in mice), so it’s unclear whether blocking Twist1 would remain beneficial over years or decades in humans. The research doesn’t yet show whether existing drugs can safely block Twist1 or what side effects might occur. Finally, the study focused on one specific protein in one specific cell type; real heart disease involves many genes and cell types working together, so blocking Twist1 alone might not be enough to prevent disease in patients.
The Bottom Line
Based on this research, future heart disease treatments might target Twist1 to prevent plaque formation and rupture. However, these findings are still in the laboratory stage. People with family histories of early heart disease should continue following proven prevention strategies: maintaining healthy weight, exercising regularly, eating a heart-healthy diet, managing blood pressure and cholesterol, and not smoking. This research doesn’t change current medical recommendations but suggests promising new directions for drug development.
This research is most relevant to people with genetic risk factors for early heart disease, cardiologists developing new treatments, and pharmaceutical companies looking for new drug targets. People with family histories of heart attacks or strokes should be aware that genetic factors like Twist1 contribute to disease risk, reinforcing the importance of lifestyle prevention. This research doesn’t yet apply to general population screening or treatment decisions.
If Twist1-targeting drugs are developed and tested in humans, it typically takes 10-15 years from laboratory discovery to FDA approval. Early-stage clinical trials might begin within 3-5 years if pharmaceutical companies prioritize this target. Benefits would likely be seen as reduced plaque progression over months to years, not immediate effects.
Frequently Asked Questions
What is Twist1 and why does it matter for heart disease?
Twist1 is a protein that controls how blood vessel cells behave. Research shows it activates during plaque formation and causes cells to become inflamed and unstable. Removing Twist1 from blood vessel cells in mice reduced plaque size and made plaques more stable, suggesting it’s a key driver of heart disease risk.
Can I get tested for Twist1 mutations to know my heart disease risk?
Genetic testing for Twist1 variants exists but isn’t yet standard for heart disease screening. While this research confirms Twist1 contributes to inherited risk, current clinical practice focuses on family history, cholesterol levels, and blood pressure. Talk to a cardiologist about genetic testing if you have early heart disease in your family.
Are there drugs that block Twist1 available now?
No Twist1-blocking drugs are currently approved for human use. This research identifies Twist1 as a promising target for future drug development, but moving from laboratory discovery to approved medications typically takes 10-15 years. Early clinical trials may begin within several years if pharmaceutical companies pursue this target.
How can I reduce Twist1 activation in my blood vessels?
While no direct Twist1 inhibitors exist yet, you can reduce the conditions that activate it: exercise regularly to normalize blood flow patterns, reduce saturated fat intake to decrease inflammation, manage stress, maintain healthy blood pressure, and avoid smoking. These proven prevention strategies address the underlying mechanisms Twist1 controls.
Does this research change how doctors should treat heart disease now?
This research doesn’t immediately change current treatment recommendations, which remain focused on statins, blood pressure medications, lifestyle changes, and procedures like stents. However, it identifies a new drug target for future development and explains why some people inherit higher heart disease risk, reinforcing the importance of aggressive prevention in high-risk families.
Want to Apply This Research?
- Track cardiovascular risk factors that influence Twist1 activation: monitor blood pressure readings, record high-fat meal intake, log exercise minutes, and note stress levels. Since Twist1 activates in areas of abnormal blood flow, tracking these modifiable risk factors helps users understand their personal plaque formation risk.
- Users can reduce Twist1 activation by improving blood flow patterns through regular aerobic exercise (which normalizes shear stress on blood vessels), reducing saturated fat intake (which triggers the inflammatory pathways Twist1 controls), and managing stress (which affects endothelial function). The app could prompt daily 30-minute exercise goals and track dietary fat intake.
- Establish baseline cardiovascular health metrics (blood pressure, cholesterol, BMI) and track changes quarterly. Monitor adherence to exercise and diet modifications that reduce inflammatory pathways. For users with family history of early heart disease, periodic medical check-ups should assess plaque progression through imaging, with app reminders for recommended screening intervals.
This research describes laboratory findings in mice and human cells that have not yet been tested in human clinical trials. The results are promising but preliminary. People should not change their heart disease prevention or treatment strategies based on this research alone. Anyone with concerns about heart disease risk, especially those with family history of early heart attacks or strokes, should consult with a cardiologist or healthcare provider about appropriate screening and prevention strategies. This article is for educational purposes and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
